Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

Karasik, Avraham; Lanzinger, Stefanie; Tan, Elise; Yabe, Daisuke; Jung Kim, Dae; Huey‐Herng Sheu, Wayne; Melzer Cohen, Cheli; W. Holl, Reinhard; Hwa Ha, Kyoung; Khunti, Kamlesh; Zaccardi, Francesco; Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah; Nyström, Thomas; Niskanen, Leo; Linnemann Jensen, Majken; Hoti, Fabian; Klement, Riho; Déruaz‐Luyet, Anouk; H. Kyaw, Moe; Koeneman, Lisette; Vistisen, Dorte; Carstensen, Bendix; Halvorsen, Sigrun; Langslet, Gisle; Fazeli Farsani, Soulmaz; Patorno, Elisabetta; Núñez, Julio

doi:10.1016/j.diabet.2022.101418

Public

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

Published in Diabetes & Metabolism • Jan 3, 2023

Authors:

Avraham Karasik

Stefanie Lanzinger

Elise Tan

Abstract

BACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies. METHODS: The EMPRISE Europe and Asia study is...

Subject

Empagliflozin

Medicine

Dipeptidyl peptidase-4

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!